Understanding Butyrophilin: Potential Drug Targets and Therapeutic Applications

Target Name: Butyrophilin

NCBI ID: P48132

Butyrophilin

Other Name(s): BTN

Understanding Butyrophilin: Potential Drug Targets and Therapeutic Applications

Butyrophilin (BTN) is a protein that is expressed in various tissues throughout the body, including muscle, heart, lungs, and the brain. It is a key regulator of muscle physiology and has been implicated in a number of diseases, including muscle weakness, myopathies, and neurodegenerative diseases. Despite its importance, the biology and function of BTN remain poorly understood.

In this article, we will explore the biology and potential drug targets of BTN. We will examine its structure and function, as well as the current research on its potential as a drug target. We will also discuss the potential clinical applications of BTN-targeted therapies and the challenges and opportunities in the development of these therapies.

Structure and Function

BTN is a member of the myosin heavy chain (MHC) family, which is a group of transmembrane proteins that play a key role in the structure and function of muscle cells. Myosin heavy chains are composed of four subunits that are arranged in a unique 尾-hierarchy, with the C-terminus of each subunit being exposed to the cytosol. This 尾-hierarchy is thought to play a role in the regulation of muscle contractions and is the target of many drugs that are used to treat myopathies.

BTN is a 14-kDa protein that is expressed in various tissues, including muscle, heart, lungs, and the brain. It is highly conserved, with only a single amino acid difference between its human and mouse forms. BTN has a unique 尾-hierarchy and is composed of four subunits: alpha, beta, gamma, and delta. The alpha subunit consists of the N-terminus and the first 11 amino acids, while the beta, gamma, and delta subunits consist of the middle and terminal regions of the protein.

BTN functions as a negative regulator of myosin synthesis and has been shown to play a role in the regulation of muscle physiology. It is expressed in muscle fibers and has been shown to interact with several other proteins that are involved in muscle function, including the myosin ATPase, the actinin protein, and the myosin light chain.

BTN has also been shown to play a role in the regulation of angiogenesis, the process by which new blood vessels are formed. It is expressed in endothelial cells and has been shown to interact with several angiogenic factors, including the bone marrow-derived growth factor (BMGF) and the vascular endothelial growth factor (VEGF).

Potential Drug Targets

BTN is a protein that has potential as a drug target due to its involvement in the regulation of muscle physiology and angiogenesis. There are several potential drug targets that have been identified for BTN, including the myosin ATPase, the actinin protein, the myosin light chain, and the BMGF.

The myosin ATPase is a protein that is involved in the regulation of muscle contractions and is a potential drug target for BTN. It is a 25-kDa protein that is expressed in muscle fibers and is composed of four subunits. The myosin ATPase is thought to play a role in the regulation of muscle contractions by controlling the release of ATP from the sarcolemma, the outer membrane of the muscle cell.

The actinin protein is a protein that is involved in the regulation of muscle physiology and is another potential drug target for BTN. It is a 24-kDa protein that is expressed in muscle fibers and is composed of four subunits. The actinin protein is thought to play a role in the regulation of muscle contractions by controlling the rate of cross-bridge cycling, the movement of the myosin heads along the myosin filament.

The myosin light chain is

Protein Name: Butyrophilin (nonspecified Subtype)

The "Butyrophilin Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about Butyrophilin comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets